Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 547

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1B
Chunk 547
---
 Australasia (FRCPA). After his
training, Dr. Eagle performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets
before moving into the pharmaceutical industry. Dr. Eagle’s qualifications to sit on our board of directors include his long and
successful career in the international pharmaceutical industry, his senior executive experience in areas such as business growth, strategic
alliances and mergers and acquisition transactions, his experience as a member of both public and private company boards in the healthcare
and life science industries, and his wealth of oncology 

Edward
MacPherson joined our company as a director in March 2024. Mr. MacPherson currently serves as Chief Growth Officer for Power
Digital, an industry leading digital marketing agency. Prior to joining Power Digital, from May 2016 to December 2023, he served as CEO
and Head of Growth for Endrock Growth & Analytics, a company he founded and sold to Power Digital. Prior to founding Endrock Growth
& Analytics, Mr. MacPherson held senior marketing and leadership positions at sunglass maker Prive Revaux (March 2018 to April 2020),
curated meal company Menud (October 2014 to April 2018) and Rejuvenetics, LLC, a distributor of health and wellness products (December
2012 to March 2016). Mr. MacPherson holds a BA in Economics from Gettysburg College. Mr. MacPherson also serves as a director of MIRA
Pharmaceuticals, Inc. (Nasdaq:MIRA)

Key
Advisor 

Dr.
Itzchak Angel, has served as our Chief Scientific Advisor to the Company since August, 2024. Since 2005, Dr. Angel has been the President and CEO
of Angel Pharmaceuticals Consulting & Technologies where he assists pharmaceutical and biotechnology companies, individuals, medical
staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development.
In this role, Dr. Angel provides strategic and operational guidance on issues related to ethical drug development to a wide range of
clients, including pharmaceutical and biotechnology companies, medical professionals, hospitals, technology transfer organizations, investors,
and research teams. His expertise spans a variety of therapeutic areas and pharmacological families and extends across the drug development
process–from research, preclinical and clinical phases, to marketing. In addition, Dr. Angel advises on regulatory affairs, business